When Multiple Objective Measures of Medication Adherence Indicate Incongruent Adherence Results

An Example with Pediatric Cancer

Bibliographic Data

ID15487545
AuthorsCaitlin J Cain (0000-0003-4141-275X, Georgetown University, corresponding author), Andrea Meisman (0000-0002-9594-8085, Cincinnati Children's Hospital Medical Center), Andrea R Meisman (Cincinnati Children's Hospital Medical Center), Kirstin Drucker (Virginia Commonwealth University), Evrosina Isaac (Virginia Commonwealth University), Evrosina I Isaac (Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, VA 23219, USA), Tanvi Verma (Virginia Commonwealth University), Jordyn Griffin (Virginia Commonwealth University), Jennifer Rohan (0000-0001-7807-3734, Virginia Commonwealth University), Jennifer M Rohan (Children’s Hospital of Richmond at Virginia Commonwealth University, Richmond, VA 23219, USA)
Year2020
Volume17
Issue6
Pages1956-1956
Publication date2020-03-17
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueInternational Journal of Environmental Research and Public Health (JOURNAL)
Journal identifiersISSN: 1661-7827 • E-ISSN: 1660-4601
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/ijerph17061956
PMID32192028
OpenAlexW3012116046
LanguageEN
Citations received2
References cited24

Previous research suggests that children and adolescents with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) often have difficulty adhering to complex treatment regimens during the maintenance phase of therapy. Measurement of treatment adherence can be done via objective (e.g., electronic monitoring (EM), pharmacological assays) or subjective methods (patient, parent, or physician reports). This paper provides an illustration of recommended strategies for comparing discrepancies between two objective measures of medication adherence (e.g., behavioral adherence using electronic monitoring versus pharmacological adherence using 6-mercaptopurine (6MP) metabolite data) within a relatively large cohort of pediatric patients with ALL or LBL ( N = 139) who had longitudinal data for both measures of medication adherence over a 15-month period. Additionally, individual- and family-level factors such as gender, socioeconomic status, household environment, and dose intensity will be examined to identify possible sources of discrepancies between adherence measures. This information will provide practical advice for physicians, healthcare providers, and psychologists in identifying nonadherence and the caveats therein so patients achieve the best possible health outcomes

Cancer · Environmental health · Family medicine · Leukemia · Lymphoblastic Leukemia · Medication adherence · Pediatric cancer · Population · Socioeconomic status · Acute Lymphoblastic Leukemia research · Adolescent and Pediatric Healthcare · Childhood Cancer Survivors' Quality of Life · Medicine · Internal Medicine

Tools

Open DOISci-HubOpen Access